Middle East & Africa Hereditary Cancer Testing Market Size & Outlook
Related Markets
MEA hereditary cancer testing market highlights
- The MEA hereditary cancer testing market generated a revenue of USD 116.0 million in 2024.
- The market is expected to grow at a CAGR of 11.5% from 2025 to 2033.
- In terms of segment, prostate cancer was the largest revenue generating cancer in 2024.
- Colorectal Cancer is the most lucrative cancer segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2025 to 2033.
MEA data book summary
| Market revenue in 2024 | USD 116.0 million |
| Market revenue in 2033 | USD 300.7 million |
| Growth rate | 11.5% (CAGR from 2025 to 2033) |
| Largest segment | Prostate cancer |
| Fastest growing segment | Colorectal Cancer |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer |
| Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Bio-Rad Laboratories Inc, CSL Ltd, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Abbott Laboratories, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Illumina Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 2.5% of the global hereditary cancer testing market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,577.6 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Cancer Testing Market Scope
Hereditary Cancer Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Invitae Corp | View profile | 1700 | 1400 16th Street, San Francisco, CA, United States, 94103 | https://www.invitae.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
Middle East & Africa hereditary cancer testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary cancer testing market will help companies and investors design strategic landscapes.
Prostate cancer was the largest segment with a revenue share of 12.76% in 2024. Horizon Databook has segmented the Middle East & Africa hereditary cancer testing market based on lung cancer, breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, uterine cancer, pancreatic cancer covering the revenue growth of each sub-segment from 2021 to 2033.
The Middle East and Africa (MEA) hereditary cancer testing market is growing steadily, driven by rising cancer incidence, increasing awareness, and expanding availability of advanced genetic testing technologies like next-generation sequencing. Key players include Illumina, Invitae Corporation, Centogene, and Eurofins Scientific.
For example, in January 2025, Diatech Pharmacogenetics Expands Collaborated with Merck for providing access to MEA population to personalized medicine in hereditary cancer. Government initiatives, improved healthcare infrastructure, and growing demand for early diagnosis and personalized treatment further propel market growth.
Despite challenges like high testing costs and regulatory hurdles, the market is projected to grow leading adoption and innovation in hereditary cancer diagnostics.
Reasons to subscribe to Middle East & Africa hereditary cancer testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa hereditary cancer testing market databook
-
Our clientele includes a mix of hereditary cancer testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa hereditary cancer testing market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa hereditary cancer testing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
MEA hereditary cancer testing market size, by country, 2021-2033 (US$M)
Middle East & Africa Hereditary Cancer Testing Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
